{"id":"6b68aced-5cca-5406-81c1-301bd169ed7d","stable_key":"6cdb37aa-8998-5ea8-829d-4f995caf98fc:l-carnitine-alc-neuropathy-harm","predicate":"worsens","statement":"At 24 weeks in the same taxane trial, the acetyl-L-carnitine arm had worse neuropathy scores and more severe neurotoxicity than placebo.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"451871f7-c4f3-5cbb-bada-714bc19ac81e","mechanism_event_label":"Longer follow-up revealed harm in that setting.","subject":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"object":{"id":"d69d84d1-506e-5bc4-a03f-accb17c14662","slug":"human-taxane-neuropathy","display_name":"Human taxane-associated peripheral neuropathy severity","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"451871f7-c4f3-5cbb-bada-714bc19ac81e","stable_key":"6cdb37aa-8998-5ea8-829d-4f995caf98fc:l-carnitine-alc-neuropathy-harm-event","event_type":"observed_relationship","label":"Longer follow-up revealed harm in that setting.","description":"At 24 weeks in the same taxane trial, the acetyl-L-carnitine arm had worse neuropathy scores and more severe neurotoxicity than placebo.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5ce394a9-6ec6-56dd-866f-37d85c0556e4","slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"d69d84d1-506e-5bc4-a03f-accb17c14662","slug":"human-taxane-neuropathy","display_name":"Human taxane-associated peripheral neuropathy severity","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"6e34c035-9371-578f-b799-fd2a14e9e40f","slug":"l-carnitine","display_name":"L-Carnitine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Same randomized trial; prespecified secondary follow-up.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Not a demonstrated molecular explanation of the harm; keep the clinical outcome visible.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Carnitine collection; isomer, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"l-carnitine","display_name":"L-Carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Longer follow-up revealed harm in that setting.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23733756/ · DOI 10.1200/JCO.2012.44.8738","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"eea0b418-e1ce-5cfe-9b60-12ff7a8fb0e4","evidence_kind":"source_excerpt","locator":"Lines 338-344","start_line":338,"end_line":344,"excerpt":"## l-carnitine-alc-neuropathy-harm\nLonger follow-up revealed harm in that setting.\nAt 24 weeks in the same taxane trial, the acetyl-L-carnitine arm had worse neuropathy scores and more severe neurotoxicity than placebo.\nModel: Same randomized trial; prespecified secondary follow-up.\nLimitations: Not a demonstrated molecular explanation of the harm; keep the clinical outcome visible.\nEvidence access: Primary abstract\nRandomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. · 2013 · https://pubmed.ncbi.nlm.nih.gov/23733756/ · DOI 10.1200/JCO.2012.44.8738","model_system":"Same randomized trial; prespecified secondary follow-up.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e2c9c42b-806a-55e2-abde-b0320ea94704","stable_key":"import-6cdb37aa-8998-5ea8-829d-4f995caf98fc","title":"L-Carnitine: synthesis, acyl-group transport, fuel selection and nutrient interactions (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"6fcd86d9d02babb48b2ce658d506afe84580ad4b242f93f11f742d934fa5b361","revision_id":"398e3b52-45bc-52e3-891e-656c19ca674f","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}